Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

Stopped (due to change in the post-marketing requirement to assess alirocumab during pregnancy)

Conditions

• Hypercholesterolemia

Interventions

• DRUG: ALIROCUMAB SAR236553 (REGN727)

Sponsor

Regeneron Pharmaceuticals

Collaborators

• [object Object]